MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve MyelofibrosisJohn Mascarenhas, Vikas Gupta, Moshe Talpaz et al.|Journal of Clinical Oncology|2023Cited by 89
Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary DataSrđan Verstovšek, Claire Harrison, Mohamed E. Salama et al.|Blood|2021Cited by 9
MPN-343: The BET Inhibitor Pelabresib Decreases Inflammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis Patients in the Phase 2 MANIFEST TrialOksana Zavidij, Patrick Trojer, Patricia J. Keller et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 4
The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem CellsJennifer A. Mertz, Mohamed E. Salama, Patricia J. Keller et al.|Blood|2020Cited by 3
Poster: MPN-343: The BET Inhibitor Pelabresib Decreases Inflammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis Patients in the Phase 2 MANIFEST TrialOksana Zavidij, Patrick Trojer, Patricia J. Keller et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 1